samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > pricing and reimbursement strategies for biopharmaceuticals
PUBLICATIONS
European Biopharmaceutical Review

Pricing and Reimbursement Strategies for Biopharmaceuticals

The international market potential for new biopharmaceuticals is expanding rapidly. However to be successful in these growing markets, manufacturers must develop effective strategies to address the exigencies of price regulation and government sponsored reimbursement schemes. Biopharmaceuticals face unique challenges. For these products, there are significant research and development costs and premium pricing is often required to offset the initial investment. Moreover, clinical trials for these products are typically designed to demonstrate safety and efficacy, but not superiority over existing agents. All countries are becoming increasingly interested in technology assessments and economic evaluations of pharmaceuticals and other medical interventions as they try to make difficult decisions on allocating funds. A lack of evidence demonstrating superiority is often cited by drug plan managers as the reason products are not included on drug plan formularies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Susan Neale and W. Neil Palmer of Palmer D'Angelo Consulting Inc

Susan Neale is a Policy Analyst with Palmer D'Angelo Consulting Inc in Ottawa, Canada. She researches emerging issues in the pharmaceutical industry and reviews health care policies in Canada and internationally.

Ms Neale has written articles and reports on a wide range of issues including pricing and reimbursement in Canada, drug plan cost drivers and global pricing strategies. She holds an MBA from York University in Toronto.

W. Neil Palmer is Principal Consultant with Palmer D'Angelo Consulting Inc, a Canadian-based consulting firm that provides strategic advice on the pricing and reimbursement of pharmaceuticals in Canada, the US and Europe. Mr Palmer is the Chair of the BIOTECanada committee concerned with price regulation of biopharmaceuticals in Canada.

He has written extensively on pricing and reimbursement issues and is a frequent speaker at pharmaceutical conferences in North America and Europe. Mr Palmer worked with the Canadian Patented Medicine Prices Review Board (PMPRB) for six years, first as a consultant and then as a senior staff member.

At the PMPRB his responsibilities included policy development, overseeing the price review of patented medicines and conducting economic research. Prior to this, he worked with the Health Division of Statistics Canada where he was responsible for economic and statistical analysis of health care costs and utilisation. After completing his studies at the University of Western Ontario, Mr Palmer began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care.


spacer
Susan Neale
spacer
spacer
spacer
W. Neil Palmer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG introduces Smart Connected Product to enable remote machine monitoring in real-time

Mumbai 12th January, 2022 - New solution improves machine efficiency, prevents breakdowns, lowers costs and reduces risks whilst providing anytime, anywhere remote monitoring. ACG, the world’s leading integrated solutions provider for pharmaceutical companies, has introduced the Smart Connected Product - a new, innovative, IIoT solution, that connects production machines at any facility and visualises relevant information on a single platform. This data can be viewed over the web on any device with a secure connection and is accessible only to authorised users.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement